COX-2 inhibitors and breast cancer

ANZ Journal of Surgery

Volumn 73, Issue 8, 2003, Pages 565-566

  Singh Ranger, Gurpreet ^a   Mokbel, Kefah ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADENOMATOUS POLYP; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NONHUMAN; PEPTIC ULCER; REVIEW; SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0041353503     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-2197.2003.02713.x     Document Type: Review

References (25)

1. Khuder SA, Mutgi AB. Breast cancer and NSAID use: A meta-analysis. Br. J. Cancer 2001; 84: 1188-92.
2. Cotterchio M, Krieger N, Sloan M, Steinegart A. Non-steroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2001; 10: 1213-17.
3. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol. 1999; 31: 551-7.
4. Rolland PH, Martin PM, Jacquerier J, Roland AM, Toga M. Prostaglandin production in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl Cancer Inst. 1980; 64: 1061-70.
5. Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER. Oestrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137: 5739-42.
6. Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER. Transcriptional regulation of CYP19 (aromatase) gene expression in adipose stromal cells in primary culture. J. Steroid Biochem. Mol. Biol. 1997; 61: 203-10.
7. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62: 632-5.
8. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl Cancer Inst. 1998; 90: 455-60.
9. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002; 62: 1676-81.
10. Kirkpatrick K, Ogunkolade W, Elkak A et al. The mRNA expression of cyclooxygenase-2 and vascular endothelial growth factor (VEGF) in human breast cancer. Curr. Med. Res. Opin. 2002; 18: 237-41.
11. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 2000; 60: 2101-3.
12. Suzui N, Sugie S, Rahman KM et al. Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenyl-imidazole [4,5-b] pyridine-induced mammary carcinogenesis in rats. Jpn J. Cancer Res. 1997; 88: 705-11.
13. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor in a rat mammary tumour model. Oncol. Rep. 2000; 7: 1377-81.
14. Takahashi Y, Kawahara F, Noguchi M et al. Activation of matrix metalloproteinase-2 in human breast cancer cells over-expressing cyclooxygenase-1 or -2. FEBS Lett. 1999; 460: 145-8.
15. Kirtikara K, Morham SG, Raghow R et al. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase-1 or cyclooxygenase-2 null cells. J. Exp. Med. 1998; 187: 517-23.
16. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer 2001; 8: 97-114.
17. Ohki S, Ogino N, Yamamoto S, Hayaishi O. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 1979; 254: 829-36.
18. Josephy PD, Eling TE, Mason RP. Co-oxidation of benzidine by prostaglandin synthase and comparison with the action of horseradish peroxidase. J. Biol. Chem. 1983; 258: 5561-9.
19. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase-2 deficient mice. Cell 1997; 91: 197-208.
20. Loftin CD, Trivedi DR, Tiano HF et al. Failure of ductus arteriosus closure and remodelling in neonatal mice deficient in cyclooxygenase-1 and -2. Proc. Natl Acad. Sci. USA 2001; 98: 1059-64.
21. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
22. Davis BJ, Lennard DE, Lee CA et al. Anovulation in cyclooxygenase-2 deficient mice is restored by prostaglandin E2 and interleukin-1 beta. Endocrinology 1999; 140: 2685-95.
23. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1274-55.
24. Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-8.
25. Bombardier C, Laine L, Reicin A et al. Group comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1520-8.